Celcuity (NASDAQ:CELC) PT Raised to $42.00 at Stifel Nicolaus

Celcuity (NASDAQ:CELC) had its price objective lifted by research analysts at Stifel Nicolaus from $39.00 to $42.00 in a report released on Monday, Benzinga reports. The firm currently has a “buy” rating on the stock. Stifel Nicolaus’ price target would indicate a potential upside of 175.23% from the company’s previous close.

Several other research analysts have also recently commented on CELC. Leerink Partnrs raised shares of Celcuity to a “strong-buy” rating in a report on Monday, July 22nd. HC Wainwright reaffirmed a “buy” rating and issued a $27.00 price objective on shares of Celcuity in a report on Thursday, August 15th. Needham & Company LLC reissued a “buy” rating and set a $23.00 target price on shares of Celcuity in a report on Thursday, August 15th. Lifesci Capital initiated coverage on Celcuity in a research note on Monday, August 26th. They issued an “outperform” rating and a $27.00 price target for the company. Finally, Leerink Partners started coverage on shares of Celcuity in a research report on Monday, July 22nd. They set an “outperform” rating and a $29.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, Celcuity presently has an average rating of “Buy” and a consensus price target of $29.17.

Celcuity Price Performance

Celcuity stock opened at $15.26 on Monday. The company has a market capitalization of $535.64 million, a price-to-earnings ratio of -5.49 and a beta of 0.75. The company has a current ratio of 14.95, a quick ratio of 14.95 and a debt-to-equity ratio of 0.54. Celcuity has a 12 month low of $8.39 and a 12 month high of $22.19. The stock’s 50 day moving average is $15.78 and its 200-day moving average is $16.61.

Celcuity (NASDAQ:CELC) last issued its quarterly earnings data on Wednesday, August 14th. The company reported ($0.62) EPS for the quarter, beating analysts’ consensus estimates of ($0.71) by $0.09. During the same period last year, the business earned ($0.66) earnings per share. Equities research analysts expect that Celcuity will post -2.54 EPS for the current year.

Institutional Trading of Celcuity

Large investors have recently bought and sold shares of the business. Quest Partners LLC lifted its holdings in shares of Celcuity by 31.3% in the second quarter. Quest Partners LLC now owns 5,788 shares of the company’s stock worth $95,000 after acquiring an additional 1,379 shares during the last quarter. SG Americas Securities LLC bought a new position in Celcuity in the 3rd quarter valued at approximately $119,000. BNP Paribas Financial Markets boosted its position in Celcuity by 78.5% in the first quarter. BNP Paribas Financial Markets now owns 8,937 shares of the company’s stock valued at $193,000 after buying an additional 3,930 shares in the last quarter. Commonwealth Equity Services LLC grew its stake in shares of Celcuity by 9.9% during the second quarter. Commonwealth Equity Services LLC now owns 16,624 shares of the company’s stock worth $272,000 after buying an additional 1,500 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC increased its holdings in shares of Celcuity by 7.8% during the second quarter. Wealth Enhancement Advisory Services LLC now owns 22,030 shares of the company’s stock worth $361,000 after buying an additional 1,600 shares in the last quarter. 63.33% of the stock is owned by institutional investors and hedge funds.

About Celcuity

Celcuity Inc, a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment.